LONDON, October 22, 2014 /PRNewswire/ --
Investor-Edge has initiated coverage on the following equities: Amicus Therapeutics Inc. (NASDAQ: FOLD), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), and Merrimack Pharmaceuticals Inc. (NASDAQ: MACK). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, October 21, 2014, the NASDAQ Composite ended at 4,419.48, up 2.40%, the Dow Jones Industrial Average advanced 1.31%, to finish the day at 16,614.81, and the S&P 500 closed at 1,941.28, up 1.96%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 735.36, up 2.65%, with the index also advancing 5.56% in the previous three trading sessions. Register for your complimentary reports on these five stocks at:
http://investor-edge.com/register
On Tuesday, shares in Amicus Therapeutics Inc. recorded a trading volume of 0.67 million shares, lower than its three months average volume of 2.39 million shares. The stock ended the day at $5.82, which was 2.02% below its previous day's closing of $5.94, and registered an intraday range of $5.74 and $6.07. Amicus Therapeutics Inc.'s shares have gained 2.83% in the previous three trading sessions and 50.78% in the last three months. Additionally, the stock has rallied 147.66% on YTD basis. The company's stock is trading above its 200-day moving average of $3.58. Furthermore, shares of Amicus Therapeutics Inc. have a Relative Strength Index (RSI) of 47.66. Sign up and read the free notes on FOLD at:
www.Investor-Edge.com/FOLD-22Oct2014
Progenics Pharmaceuticals Inc.'s stock lost 2.08%, to close Tuesday's session at $4.70, after oscillating between $4.65 and $4.87. The stock recorded a trading volume of 0.60 million shares, below its three months average volume of 0.94 million shares. Over the last three trading sessions and previous three months, Progenics Pharmaceuticals Inc.'s shares have fallen by 3.09% and 4.67%, respectively. Additionally, the stock has declined 11.82% since the start of this year. The company's stock is trading above its 200-day moving average. The stock's 50-day moving average of $5.09 is above its 200-day moving average of $4.64. Further, Progenics Pharmaceuticals Inc.'s stock has an RSI of 47.02. The complimentary notes on PGNX can be downloaded as in PDF format at:
www.Investor-Edge.com/PGNX-22Oct2014
Threshold Pharmaceuticals Inc.'s stock finished Tuesday's session 0.33% higher at $3.00. A total of 0.45 million shares were traded, which was below its three months average volume of 0.72 million shares. The stock moved between $2.92 and $3.03 during the session. Threshold Pharmaceuticals Inc.'s shares have plummeted 32.89% in the last one month and 27.54% in the previous three months. Additionally, from the beginning of 2014, the stock has declined 35.76%. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $4.28 is greater than its 50-day moving average of $3.93. Threshold Pharmaceuticals Inc.'s stock has an RSI of 27.48. Register for free on Investor-Edge and access the latest research on THLD at:
www.Investor-Edge.com/THLD-22Oct2014
On Tuesday, shares in Idera Pharmaceuticals Inc. fluctuated between $2.26 and $2.39 before ending the session 3.48% higher at $2.38. The stock reported a trading volume of 0.66 million shares, below its three months average volume of 0.82 million shares. Although, Idera Pharmaceuticals Inc.'s shares have advanced 1.28% in the previous three trading sessions, it has lost 3.25% in the last one month and 48.60% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages of $2.49 and $3.44, respectively. Moreover, shares of Idera Pharmaceuticals Inc. have an RSI of 50.00. The complete research on IDRA is available for free at:
www.Investor-Edge.com/IDRA-22Oct2014
Merrimack Pharmaceuticals Inc.'s stock closed the day flat at $8.68. The stock recorded a trading volume of 1.26 million shares, below its three months average volume of 1.88 million shares. The stock oscillated between $8.45 and $8.80 during the session. Over the last one month and over the past three months, Merrimack Pharmaceuticals Inc.'s shares have gained 19.07% and 47.12%, respectively. Further, the stock has surged 62.82% since the beginning of this year. The company's stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $7.46 is above its 200-day moving average of $6.39. Additionally, Merrimack Pharmaceuticals Inc. has an RSI of 59.29. Free in depth research on MACK is available at:
www.Investor-Edge.com/MACK-22Oct2014
About Investor-Edge.com
At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Investor-Edge
